Thomas Durand-Réville

Thomas started his medicinal chemistry career at Biogen and Wyeth where he worked on several oncology and inflammation projects. Later, in the AstraZeneca Infection group, he was responsible for the medicinal chemistry strategy on many programs from early stage hit identification through IND-enabling studies. These efforts culminated in the discovery of durlobactam (which recently completed Phase 3 clinical trials). He then became the head of chemistry at Entasis Therapeutics (spin-off company from the AstraZeneca Infection department), where his group focused on delivering a portfolio of innovative new antibiotics against multidrug-resistant Gram-negative pathogens.

At Dewpoint, Thomas is building the medicinal chemistry team in Boston and supporting various drug discovery programs across multiple Disease Areas.